OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial
Aesthetic Surgery Journal · 2025
DOI: 10.1093/asj/sjaf204 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Aesthetic Surgery Journal, 2025. Verfasst von Jiaming Sun und 15 weiteren Autor:innen. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Masseter Muscle, Neuromuscular Agents. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan Aesthetics, an AbbVie company, Shenavia Balcom-Luker, AbbVie Inc.
Abstract (Originalsprache)
Background
Masseter muscle prominence (MMP) may be aesthetically bothersome to some individuals, leading them to seek treatment for a slimmer lower face.
Objectives
The aim of this study was to evaluate the safety and efficacy of onabotulinumtoxinA for the treatment of MMP, including patient-reported outcomes (PROs).
Methods
This was a prospective, multicenter trial including a randomized, double-blind, placebo-controlled period (Days 1−180) in which adults rated Grade 4 or 5 (marked/very marked) on the investigator-assessed MMP Scale (MMPS) were randomized to onabotulinumtoxinA 72 U or placebo. Efficacy endpoints were assessed at Day 90. The primary endpoint was ≥2-grade improvement from baseline on the investigator-assessed MMPS. Secondary endpoints included achieving Grade ≤3 on the MMPS and participant-assessed MMPS—Participant (MMPS-P), ≥2-grade improvement on the participant-assessed MMPS-P, and change from baseline in lower-facial width. Outcomes were assessed using validated measures. Adverse events (AEs) were monitored.
Results
Of 376 enrolled participants (onabotulinumtoxinA, n = 283; placebo, n = 93), 310 (82.4%) completed the study. At Day 90, a greater proportion of onabotulinumtoxinA-treated participants vs placebo achieved MMPS ≥2-grade improvement (51.2% vs 2.2%, P < .0001), and more onabotulinumtoxinA-treated participants vs placebo achieved the secondary endpoints (all P < .0001), with a mean lower-facial width reduction of −5.24 mm for onabotulinumtoxinA vs −0.04 mm for placebo (P < .0001). Participants reported benefits for onabotulinumtoxinA vs placebo in self-perceived change in MMP, treatment satisfaction, and psychosocial impact. Improvements were sustained through Day 180. Most AEs were mild, nonserious, and resolved.
Conclusions
OnabotulinumtoxinA effectively reduced the appearance of MMP and improved PROs, with effects lasting up to 6 months and a favorable safety profile. Level of Evidence: 1 (Therapeutic)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Shannon Humphrey, William McGillivray, Shu-Hung Huang, Catherine Foley, Donna L Faletto
Förderung
- Allergan Aesthetics, an AbbVie company
- Shenavia Balcom-Luker
- AbbVie Inc
- LLC
Zitieren
APA
Sun, J., Wang, L., Wu, Y., Humphrey, S., Chen, S. G., McGillivray, W., Huang, S. H., Zhang, Y., Pan, G., Foley, C., Lee, E., Chang-Lin, J. E., Faletto, D. L., Patel, V., Bowen, B., & Brin, M. F. (2025). OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjaf204
Vancouver
Sun J, Wang L, Wu Y, Humphrey S, Chen SG, McGillivray W, et al. OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial. Aesthetic Surgery Journal. 2025. doi:10.1093/asj/sjaf204
BibTeX
@article{Sun2025,
author = {Sun, Jiaming and Wang, Lei and Wu, Yan and Humphrey, Shannon and Chen, Shyi-Gen and McGillivray, William and Huang, Shu-Hung and Zhang, Yuguang and Pan, Grace and Foley, Catherine and Lee, Elisabeth and Chang-Lin, Joan-En and Faletto, Donna L and Patel, Vaishali and Bowen, Beta and Brin, Mitchell F},
title = {OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial},
journal = {Aesthetic Surgery Journal},
year = {2025},
doi = {10.1093/asj/sjaf204}
}
EUVIMED